Resverlogix Clears Cease Trade Order After Filing 2025 Annual Results

An update from Resverlogix ( (TSE:RVX) ) is now available.

Resverlogix Corp. has regained full management trading privileges after the Alberta Securities Commission revoked a management cease trade order effective April 15, 2026. The order had applied only to the chief executive and chief financial officers and followed a delay in annual filings, which the company completed on April 10, 2026.

With its audited financial statements and related annual disclosures for 2025 now filed, Resverlogix says it is current with all disclosure requirements and expects to meet future deadlines. The resolution of the compliance issue removes a regulatory overhang for the biotech, helping stabilize its market standing as it advances development of its epigenetic drug candidate apabetalone.

Spark’s Take on RVX Stock

According to Spark, TipRanks’ AI Analyst, RVX is a Neutral.

The score is primarily constrained by very weak financial performance (no revenue, sustained losses and cash burn, and negative equity with heavy leverage). Technicals provide only a modest offset due to mixed signals and negative momentum indicators, while valuation remains challenged because the company is loss-making and offers no dividend yield.

To see Spark’s full report on RVX stock, click here.

More about Resverlogix

Resverlogix Corp. is a Calgary-based late-stage biotechnology company specializing in epigenetic therapies aimed at regulating disease-causing genes. Its lead drug candidate, apabetalone, is being evaluated for cardiovascular disease, related comorbidities, and post-COVID-19 conditions, with shares listed on the Toronto Stock Exchange under the symbol RVX.

Average Trading Volume: 38,507

Technical Sentiment Signal: Sell

Current Market Cap: C$33.2M

Find detailed analytics on RVX stock on TipRanks’ Stock Analysis page.